Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2024 | Targeting MCL1-mediated survival to overcome HMA resistance in CMML

Guillermo Montalban-Bravo • 15 Jun 2024
EHA 2024
Chronic Myelomonocytic Leukemia Leukemia Rare Diseases Venetoclax

Guillermo Montalban-Bravo, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the targeting of MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent (HMA) resistance in chronic myelomonocytic leukemia (CMML) with RAS pathway mutations. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Guillermo Montalban-Bravo

1:12
Clinical implications of extramedullary manifestations in CMML
Guillermo Montalban-Bravo • 15 Jun 2024
1:37
A Phase I/II trial of seclidemstat in combination with azacitidine for patients with MDS and CMML
Guillermo Montalban-Bravo • 15 Jun 2024

Related Videos

2:57
Novel targeted therapies for the treatment of BPDCN
Muzaffar Qazilbash • 30 Jul 2024
1:59
Phase I study of pevonedistat, azacitidine, and venetoclax in patients with R/R AML
Guru Subramanian Guru Murthy • 11 Jul 2024
1:53
Advancements in prolonging remission post-transplant
Guru Subramanian Guru Murthy • 11 Jul 2024
2:32
Tools and biomarkers being used for the diagnosis of BPDCN
Muzaffar Qazilbash • 30 Jul 2024
The content of VJHemOnc is intended for healthcare professionals